On my way home from San Francisco, I checked my Function Health results. My PSA was 5.0, which is higher than the usual cut-off of 4. Only 10% of my PSA was floating free in the blood, but the report said it should be over 25%. The clinician note called this “a red flag” and told me to see a urologist “as soon as reasonably possible, even if you are asymptomatic.”
I’m a doctor, so I know PSA levels can change for harmless reasons. I stayed calmer than the note suggested, but I still made an appointment with a urologist.
That happened in May. Now it’s Movember, when men grow mustaches to raise awareness for men’s health and prostate cancer. So I’m sharing my full story, numbers and all.
A lot of men see a PSA test as a final verdict on cancer. That makes some delay the test, while others panic if their number is high. My verdict: Keep. Get your first PSA test between ages 45 and 50, or earlier if you’re at higher risk. Before you get your blood drawn, decide what you’ll do if the result is high, i.e., repeat the test, then get an MRI before any biopsy.
Why men wait
My urologist is a woman. She performed the rectal exam, where a gloved finger checks the prostate from behind.
I know a lot of men who skip the appointment because of that exam. Come on, guys, women have to go through gynecologist exams that aren’t enjoyable either. They don’t get to skip theirs, and neither should we.
I think of this as a case where information loses to incentives. You get a calendar invite for your Tuesday meeting, but not for your prostate. The appointment means one awkward morning now, while any benefit is years away. When life is busy, it’s easy to keep putting it off.
The odd part: the finger exam is on its way out as a screening test. Germany’s 2025 guideline says doctors should not use it for early detection [1]. Australia’s 2026 guideline suggests family doctors leave it out of screening [2]. Europe’s urologists now base screening on PSA and your personal risk [3]. A urologist may still examine you after a high result, as mine did. The screening test itself is a blood draw.
Germany has its own mismatch. Public insurance still pays for the yearly check from age 45 that includes the finger exam. It doesn’t pay for the PSA test [4]. So insurance pays for the exam that Germany’s own guideline advises against, and you usually pay for the blood test yourself. A decision on covering PSA plus MRI is due by October 2027 [4].
I’ll stick to the basics you’d need when talking to your own doctor: just a few key numbers. You can find more details in the references.
Screening saves lives, slowly
The largest European trial invited men aged 55 to 69 to regular PSA tests and followed them for 23 years [5]. In the invited group, 13% fewer men died of prostate cancer. In plain numbers: one death prevented for every 456 men invited. For each death prevented, 12 extra men were diagnosed.
Some of those 12 men had cancers that would never have caused them problems. That’s the downside of screening: it can lead to worry, biopsies (where needle samples are taken from the prostate), and sometimes treatment for a cancer that would have stayed silent.
A British trial shows what happens when doctors watch instead of treating [6]. Men whose cancer was found through PSA testing were either monitored, operated on, or treated with radiation. After 15 years, about 97 in 100 had not died of prostate cancer, whatever their group. Monitoring wasn’t free: the cancer spread more often in the monitored men. Watching means real check-ups, not forgetting.
The strongest case against: in a June 2026 draft, Germany’s institute for medical evidence, IQWiG, said it could not yet show a benefit for PSA plus MRI screening, because the long-term data don’t exist yet [7].
The doctor’s take: the benefit for one person is small, but it’s real when you look at thousands of men. I’m willing to take a 1-in-456 chance on a blood test, as long as the next steps are careful. Doing an MRI first, only doing a biopsy when needed, and monitoring slow-growing cancers help avoid much of the harm that made screening unpopular.
One number at 45 tells you a lot
A Swedish study measured PSA in stored blood from men in their 40s and followed them for 25 years [8]. Men in the top tenth at age 45 to 49, with a PSA of 1.6 or more, accounted for 44% of later prostate cancer deaths. At 1.0 or below, fewer than 1 in 100 died of prostate cancer within 25 years.
That’s why guidelines now suggest having your first test in your mid-40s. The result helps decide how often you need to come back. In Germany, if your value is below 1.5, you wait five years for the next test [1].
The American Urological Association says doctors may offer a first PSA between 45 and 50. For Black men, men with inherited gene changes such as BRCA2, and men with a strong family history, doctors should offer it from 40 to 45 [9].
A high PSA is a question
PSA is a protein made by the prostate. Cancer can raise PSA levels, but so can many everyday things.
Two common reasons are prostate size and inflammation [10]. The prostate gets bigger as you age, and a larger gland makes more PSA. Ejaculation can raise PSA for a day or two [11]. Finasteride, which is used for hair loss or an enlarged prostate, lowers PSA by about 40 to 50% even at the hair-loss dose [12]. Be sure to tell your doctor if you take it, or a high PSA could be hidden.
PSA levels can also change on their own. In one American study, about 4 out of 10 men with a high PSA had a normal result at one or more later yearly checkups [13]. That’s why the first step after a high PSA is to repeat the test, ideally in the same lab and using the same method [3].
My Berlin retest came back at 5.57. Still high.
Where the 25% comes from
The 25% cutoff for free PSA comes from a 1998 American study [14]. The study looked at men aged 50 to 75 with PSA levels between 4 and 10, and nearly half had cancer. Using 25% as the cutoff, 95 out of 100 men with cancer fell below it, but so did about 80 out of 100 men whose biopsies were normal. Cancer usually lowers the free PSA percentage, which is why labs worry about a low number. This cutoff is meant to catch almost everyone with cancer, so it makes sense for men already heading for a biopsy. But it can’t predict the risk for a healthy 47-year-old.
I was 47, had no symptoms, and was tested as part of a panel with over 100 markers. My Berlin lab uses 15% as the cutoff for the same ratio. Same person, same month, but two different cutoffs.
Show me the study. Every exact cutoff is based on research done with a specific group of men, so it’s fair to ask who was included.
The doctor’s take: to be fair to Function Health, their advice was correct: see a urologist. The issue was calling it a “red flag.” Big test panels for healthy people often lead to this: a slightly unusual number, a scan, and days of worry. Most of the time, it’s a false alarm. When it’s not, you’re glad you checked. For your prostate, a simple plan works best: one PSA test in your mid-40s and a clear next step is better than 100 numbers with no plan.
I chose by calendar
My urologist gave me two options and explained them as equally good choices.
One option was an MRI scan of the prostate. The other was micro-ultrasound, a high-resolution ultrasound performed by one of the few specially trained examiners in Berlin. The advantage of micro-ultrasound is that if the examiner finds something, they can do a biopsy during the same visit.
I looked at the evidence and was open to either option. Then I checked my calendar. The MRI was available on June 1, while the ultrasound was scheduled for mid-June. I chose the earlier date.
Since then, I’ve learned about a randomized trial called OPTIMUM, done in 20 centers across 8 countries [15]. With certified examiners, micro-ultrasound found aggressive cancers about as often as MRI-guided biopsy. But there are two issues. All 678 men in the analysis had a biopsy, regardless of what their scan showed, so the trial couldn’t test whether a clean ultrasound means you can skip the biopsy. The device maker also funded the trial. Current guidelines still recommend MRI first [3].
The main advantage of MRI is that it can let you avoid a biopsy. In an earlier study, 28% of men had a clean MRI and didn’t need a biopsy at all [16]. With the ultrasound option, you’re usually already set up for a biopsy.
The doctor’s take: both options are good if you have an experienced examiner. Ask how many procedures they’ve done. If you need a biopsy, ask if it can be done through the skin between the scrotum and anus instead of through the rectum. European guidelines now strongly recommend this approach because it lowers the risk of infection [3].
What the MRI found
No area that looked like cancer. PI-RADS 2, on a scale where 1 and 2 mean significant cancer is unlikely.
The scan showed a mildly enlarged prostate and signs of chronic inflammation. My report found two common reasons for a high PSA. No scan can say for sure which one caused my high PSA.
For a result like mine, with no family history and a PSA level that matches the size of my prostate, the European guideline recommends checking PSA again over time instead of doing a biopsy [3]. Even a clean MRI can miss cancer, so follow-up is important. My urologist wants me to have my PSA checked again in a year.
This fits into the Capacity pillar of my Upward ARC framework. Work and life add to your load, and capacity is what helps you handle it at age 50 or 70. One blood test at 45 is a small cost, and it tells you if you need to come back in two years or five.
My verdicts
- First PSA between 45 and 50, or 40 to 45 if you’re at higher risk: Keep.
- Repeat a high PSA before anything else: Keep.
- MRI before any biopsy: Keep.
- Micro-ultrasound with a biopsy in the same visit: Situational. Reason: it’s industry-funded. Good results with certified experts, in one trial paid for by the device maker, and no test yet showing you can skip the biopsy after a clean scan.
- The finger exam as a screening test: Cut. Reason: wrong direction. Germany’s guideline gives it the strongest grade to exclude it.
- A “red flag” from a 25% free-PSA cutoff at 47, on a 100-marker panel: Situational. Reason: I’m the wrong population.
Try this today
- Figure out when to start: between 45 and 50, or earlier if you’re at higher risk (if you’re Black, have a BRCA2 gene change, or close relatives with prostate cancer, especially if they were diagnosed young). Ask your doctor which category you’re in, then schedule the blood test.
- Don’t ejaculate for 48 hours before the blood draw [11]. Bring a list of your medications, especially if you take finasteride or testosterone.
- If your PSA result is high, repeat the test. If it’s still high, get an MRI before any biopsy, and ask if the biopsy can be done through the skin.
This coming week I’m in Boston, and will do my second Function Health test of the year. Same app, similar panel of biomarkers, but this time a more educated reader. I know what the 25% line was built for, I know what my prostate looks like on an MRI, and I know what can impact the PSA numbers.
Two documents sit in my folder now. The first came from an app, in English, with a red flag and “as soon as reasonably possible.” The second came from a radiology practice in Berlin: two pages of German so dry it could pass for a tax notice. It wasn’t even addressed to me. It went to my urologist, about “Ihren o.g. Patienten.” Your above-named patient.
I’ve written that phrase into more doctor’s letters than I can count. It’s strange to be the “o.g. Patient.”
The verdict took three words: “keine malignomsuspekten Läsionen.” No lesions suspicious for cancer. Nobody has ever made me happier by being boring.
Have you had your PSA checked? If not, what’s held you back? Reply and let me know. I read every message.
Stay healthy.
Andre
PS: If you don’t have a prostate, someone you care about does. Please forward this to him and ask when his test is scheduled. That’s how this newsletter grows, and it’s the only way I want it to.
PPS: If a friend sent you this, you can get Under Load, my Sunday edition, here: https://www.andreheeg.com
References
[1] Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). (2025). S3-Leitlinie Prostatakarzinom, Kurzversion 8.1 (AWMF-Registernummer 043-022OL). https://register.awmf.org/assets/guidelines/043-022OLk_S3_Prostatakarzinom_2026-05.pdf
[2] Prostate Cancer Foundation of Australia. (2026). 2026 guidelines for the early detection of prostate cancer in Australia: Summary of recommendations. https://www.prostate.org.au/wp-content/uploads/2026/08/2026-Guidelines-for-the-Early-Detection-of-Prostate-Cancer-Summary-of-Recommendations.pdf
[3] Cornford, P., Tilki, D., van den Bergh, R. C. N., et al. (2026). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer (limited text update, March 2026). European Association of Urology. https://uroweb.org/guidelines/prostatecancer/chapter/diagnostic-evaluation
[4] Gemeinsamer Bundesausschuss. (2025, October 16). Früherkennung von Prostatakrebs: G-BA prüft risikoabhängiges Angebot [Press release]. https://www.g-ba.de/presse/pressemitteilungen-meldungen/1290/
[5] Roobol, M. J., de Vos, I. I., Månsson, M., et al. (2025). European study of prostate cancer screening: 23-year follow-up. New England Journal of Medicine, 393(17), 1669–1680. https://doi.org/10.1056/NEJMoa2503223
[6] Hamdy, F. C., Donovan, J. L., Lane, J. A., et al. (2023). Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 388(17), 1547–1558. https://doi.org/10.1056/NEJMoa2214122
[7] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. (2026, June 16). Risikoadaptiertes PSA- und MRT-Screening: Vorbericht S25-02, Version 1.0. https://www.iqwig.de/download/s25-02_risikoadaptiertes-psa-und-mrt-screening_vorbericht_v1-0.pdf
[8] Vickers, A. J., Ulmert, D., Sjoberg, D. D., et al. (2013). Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: Case-control study. BMJ, 346, f2023. https://doi.org/10.1136/bmj.f2023
[9] Lin, D. W., Carlsson, S., Filson, C. P., Kim, S. K., Kirkby, E., Konety, B. R., Purysko, A. S., & Souter, L. H. (2026). Updates to early detection of prostate cancer: AUA/SUO guideline (2026). The Journal of Urology, 215(5), 491–501. https://doi.org/10.1097/JU.0000000000004995
[10] Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J., & Ratliff, T. L. (1995). Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. Journal of Urology, 154(2 Pt 1), 407–413. https://doi.org/10.1097/00005392-199508000-00023
[11] Tchetgen, M. B., Song, J. T., Strawderman, M., Jacobsen, S. J., & Oesterling, J. E. (1996). Ejaculation increases the serum prostate-specific antigen concentration. Urology, 47(4), 511–516. https://doi.org/10.1016/S0090-4295(99)80486-5
[12] D’Amico, A. V., & Roehrborn, C. G. (2007). Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: A randomised controlled trial. Lancet Oncology, 8(1), 21–25. https://doi.org/10.1016/S1470-2045(06)70981-0
[13] Eastham, J. A., Riedel, E., Scardino, P. T., Shike, M., Fleisher, M., Schatzkin, A., Lanza, E., Latkany, L., & Begg, C. B. (2003). Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations. JAMA, 289(20), 2695–2700. https://doi.org/10.1001/jama.289.20.2695
[14] Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N., Parson, R. E., Gasior, G. H., Loveland, K. G., & Southwick, P. C. (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA, 279(19), 1542–1547. https://doi.org/10.1001/jama.279.19.1542
[15] Kinnaird, A., Luger, F., Cash, H., Ghai, S., Urdaneta-Salegui, L. F., Pavlovich, C. P., et al. (2025). Microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis: The OPTIMUM randomized clinical trial. JAMA, 333(19), 1679–1687. https://doi.org/10.1001/jama.2025.3579
[16] Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., et al. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine, 378(19), 1767–1777. https://doi.org/10.1056/NEJMoa1801993
Editor's note
Editorial clarification and evidence update
The Upward ARC is an educational newsletter for a general audience, not a medical publication. It may use ordinary-language metaphors and simplifications to make complex evidence readable. Those phrases are not clinical terminology. The editorial standard remains unchanged: do not fabricate, cite falsely, hide important uncertainty, or simplify a point so far that it changes the practical meaning.
Updated November 10, 2026. The historical edition above remains unchanged.
What one in 456 measures: One prostate cancer death was prevented per 456 men invited to repeated screening over 23 years. The trial’s main analysis covered ages 55 to 69 at entry. The figure cannot estimate the benefit of a single blood test at 47. [1]
When to repeat a high PSA: The European recommendation to repeat PSA before further testing applies to asymptomatic men with a moderately elevated result of 3 to 10 ng/mL. Symptoms, examination findings and substantially higher values can call for a different diagnostic pathway. [2]
References
- Roobol, M. J., de Vos, I. I., Månsson, M., et al. (2025). European study of prostate cancer screening: 23-year follow-up. New England Journal of Medicine, 393(17), 1669–1680.
- Cornford, P., Tilki, D., van den Bergh, R. C. N., et al. (2026). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer (limited text update, March 2026). European Association of Urology.
For informational and educational purposes only. This page does not provide individual medical advice, diagnosis, or treatment. Read the full medical disclaimer.